A Phase 1, Study of BMF-500 in Adults With Acute Leukemia

Study Number
3559023
Phase
I
Age Group
Adult
Principal Investigator
Eunice S. Wang
Purpose

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

Check your eligibility for this trial
Check now
Full Title

A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

ClinicalTrials.Gov ID
NCT05918692

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.